Quercis Pharma And Thomas Lines Nominated For Prestigious Prix Galien USA “Best Startup” Award, Recognizing Innovation In Biopharma

Quercis Pharma AG, a clinical-stage biopharmaceutical company developing inflammasome-modulating therapies for oncology, thrombosis, and inflammatory diseases, has announced that it, along with its founder Thomas Lines, has been nominated for the 2025 Prix Galien USA Award in the “Best Startup” category. The Prix Galien, often referred to as the “Nobel Prize of Biopharmaceutical Research,” is one of the life sciences industry’s most prestigious honors, recognizing exceptional innovation that improves human health. The winners will be revealed on October 30, 2025, during the Prix Galien USA Awards Ceremony at the American Museum of Natural History in New York City.

Thomas Lines, Chief Executive Officer of Quercis Pharma, said, “This nomination is an important recognition of our mission to develop accessible inflammasome-modulating therapies that can improve outcomes for patients facing life-threatening conditions such as cancer, thrombosis, and sickle cell disease. Science matters most when it touches lives. At Quercis, we measure innovation not only by new drug discoveries but also by our ability to make these therapies accessible, affordable, and equitable for patients everywhere. Being recognized alongside such a remarkable group of innovators is a great honor and a humbling experience that motivates us to deliver on our promises.”

Quercis Pharma has been recognized for its pioneering antithrombotic platform and its strong clinical pipeline. This includes an ongoing Phase 3 study evaluating therapies to reduce life-threatening blood clots in cancer patients while minimizing the bleeding risks associated with current treatments. The company also has two Phase 3-ready programs targeting oncology and sickle cell disease, along with a robust Phase 2 pipeline addressing solid tumors, viral diseases, ALS, and COPD, all of which represent areas of significant unmet medical need.

Bruno Cohen, Chairman of the Galien Foundation, commented, “We are honored to recognize this year’s outstanding Prix Galien USA nominees, whose innovation in medical technology, digital health, and entrepreneurship demonstrates the progress that moves healthcare forward. Their achievements highlight the extraordinary potential of science to change lives.”

The Prix Galien USA winner for “Best Startup” will be announced on October 30 in New York, celebrating the most innovative and impactful contributions to healthcare from emerging companies.